The U.S. Centers for Medicare and Medicaid Services (CMS) on Wednesday said it has finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc and Novartis AG .
Source:: Reuters – Business News
Newswire
- [ April 30, 2026 ] Myseum.AI (NASDAQ: MYSE) Appoints Ian Goldberg as Head of Marketing, Partnerships & Monetization Newsmakers
- [ April 30, 2026 ] TOMI Environmental Solutions (NASDAQ: TOMZ) Signs Letter of Intent for a Merger with Carbonium Core, Inc., a U.S.-Based Producer of Nuclear-Grade Graphite for Advanced Reactors and Infrastructure Demands of AI Data Centers Newsmakers
- [ April 29, 2026 ] TOMI Environmental Solutions (NASDAQ: TOMZ) Targets $70 Billion U.S. Drone and Defense Budget with Autonomous SteraMist iHP Decontamination Newsmakers
- [ April 27, 2026 ] TOMI Environmental Solutions (NASDAQ: TOMZ) Sees Strong Interest In Its Solutions at INTERPHEX 2026 Newsmakers
- [ April 27, 2026 ] TOMI Environmental Solutions (NASDAQ: TOMZ) Scales Automation with SteraMist iHP Robot Upgrade; Targets Fast Growing Robotaxi Market Newsmakers
- [ April 27, 2026 ] Myseum.AI (NASDAQ: MYSE) to Debut Picture Party for Couples at the Florida Bridal & Wedding Expo Newsmakers
- [ April 15, 2026 ] Myseum (NASDAQ: MYSE) Rebrands as Myseum.AI to Align with Full Suite of Technology and Social Media Platforms Newsmakers
- [ April 6, 2026 ] Myseum (NASDAQ: MYSE) Brings Free Private Social Network to 10,000 Weddings Where Every Guest Becomes the Photographer Newsmakers
- [ April 1, 2026 ] Next Super Stock Myseum (NASDAQ: MYSE) $100 Billion Opportunity: $MYSE is What Instagram was Meant to Be! CEO Interview
- [ April 1, 2026 ] Myseum (NASDAQ: MYSE) Launches New Subscription-Based Enterprise Platform Service Picture Party for Business Newsmakers
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.